
SNWV Stock Forecast & Price Target
SNWV Analyst Ratings
Bulls say
SANUWAVE Health reported a significant financial performance in 2024, achieving a remarkable 60% year-over-year revenue growth, amounting to $32.6 million, largely driven by increased sales of its FDA-approved systems and consumables. The company's commitment to regenerative medicine through noninvasive technologies is underscored by a notable improvement in adjusted EBITDA, which increased by 28 points to 22%. While operating expenses rose to $6.4 million, primarily due to non-cash compensation and NASDAQ fees, the substantial revenue growth and rising profitability metrics suggest a strong and positive financial outlook for SANUWAVE Health.
Bears say
SANUWAVE Health has recently experienced a decline in applicator usage during the first quarter, a trend attributed to seasonal patient behavior influenced by the resetting of annual insurance deductibles in January. Additionally, the company faces several challenges, including margin compression, competitive pressures, decreased productivity among sales representatives, and potential manufacturing issues, which could negatively impact its financial performance. These factors collectively contribute to a negative outlook for SANUWAVE Health's stock, as they may hinder the company's ability to achieve anticipated growth and profitability.
This aggregate rating is based on analysts' research of SANUWAVE Health Inc and is not a guaranteed prediction by Public.com or investment advice.
SNWV Analyst Forecast & Price Prediction
Start investing in SNWV
Order type
Buy in
Order amount
Est. shares
0 shares